Sickle Cell Disease
Conditions
Interventions
pethidine
morphine
Sponsors
Hills Pharmacy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All consenting adult sickle cell patients; 18 years and above who presented to the facility in acute pain crisis; with a minimum pain score of 7 on the McCaffery et al Pain Scale108 during the period of the study.
Exclusion criteria
Exclusion criteria: 1. History of opioid allergy or adverse effect to opioid use. 2. Urine dipstix of greater than 2+ proteinuria. 3. History of moderate to severe liver disease, or moderate to severe jaundice. 4. Pregnant women. 5. Patients with cognitive impairment. 6. Uncontrolled seizure disorder 7. Uncontrolled asthma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of the study was the proportion of participants in each group whose admission pain reduced from a rating of at least seven to a level of or below three (and remained so continuously for 24 hours) within 72 hours after the commencement of drug administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures were, the time taken for the initial pain to reduce by a margin of at least 2 within a 6-hour period (even if the pain went up thereafter), as well as the incidence of adverse events in the two treatment groups. | — |
Countries
Ghana
Contacts
Public ContactFranklin Acheampong
Head of Research
Outcome results
None listed